###begin article-title 0
###xml 75 79 <span type="species:ncbi:10090">Mice</span>
Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice
###end article-title 0
###begin p 1
Conceived and designed the experiments: RB RLM PHG SP HEG. Performed the experiments: RB RLM ADR AD VJL. Analyzed the data: RB RLM AD PHG HEG. Contributed reagents/materials/analysis tools: ADR VJL PHG SP. Wrote the paper: RB RLM HEG.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 250 255 <span type="species:ncbi:9606">human</span>
###xml 307 311 <span type="species:ncbi:10090">mice</span>
###xml 336 344 <span type="species:ncbi:9606">patients</span>
Innate neuroimmune dysfunction is a pathobiological feature of amyotrophic lateral sclerosis (ALS). However, links, if any, between disease and adaptive immunity are poorly understood. Thus, the role of T cell immunity in disease was investigated in human G93A superoxide dismutase 1 (SOD1) transgenic (Tg) mice and subsequently in ALS patients.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 625 626 625 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 668 669 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 715 716 715 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 941 942 941 942 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 946 947 946 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 980 981 980 981 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 985 986 985 986 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
###xml 873 877 <span type="species:ncbi:10090">mice</span>
###xml 1025 1029 <span type="species:ncbi:10090">mice</span>
Quantitative and qualitative immune deficits in lymphoid cell and T cell function were seen in G93A-SOD1 Tg mice. Spleens of Tg animals showed reductions in size, weight, lymphocyte numbers, and morphological deficits at terminal stages of disease compared to their wild-type (Wt) littermates. Spleen sizes and weights of pre-symptomatic Tg mice were unchanged, but deficits were readily seen in T cell proliferation coincident with increased annexin-V associated apoptosis and necrosis of lymphocytes. These lymphoid deficits paralleled failure of Copolymer-1 (COP-1) immunization to affect longevity. In addition, among CD4+ T cells in ALS patients, levels of CD45RA+ (naive) T cells were diminished, while CD45RO+ (memory) T cells were increased compared to age-matched caregivers. In attempts to correct mutant SOD1 associated immune deficits, we reconstituted SOD1 Tg mice with unfractionated naive lymphocytes or anti-CD3 activated CD4+CD25+ T regulatory cells (Treg) or CD4+CD25- T effector cells (Teff) from Wt donor mice. While naive lymphocytes failed to enhance survival, both polyclonal-activated Treg and Teff subsets delayed loss of motor function and extended survival; however, only Treg delayed neurological symptom onset, whereas Teff increased latency between disease onset and entry into late stage.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 238 243 <span type="species:ncbi:9606">human</span>
###xml 359 364 <span type="species:ncbi:9606">human</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
A profound and progressive immunodeficiency is operative in G93A-SOD1 mice and is linked to T cell dysfunction and the failure to elicit COP-1 neuroprotective immune responses. In preliminary studies T cell deficits were also observed in human ALS. These findings, taken together, suggest caution in ascribing vaccination outcomes when these animal models of human ALS are used for study. Nonetheless, the abilities to improve neurological function and life expectancy in G93A-SOD1 Tg mice by reconstitution with activated T cells do provide opportunities for therapeutic intervention.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 89 92 89 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Boillee1">[1]</xref>
###xml 94 97 94 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Lobsiger1">[2]</xref>
###xml 184 187 184 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Rosen1">[3]</xref>
###xml 286 289 286 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Gurney1">[4]</xref>
###xml 290 293 290 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Turner1">[7]</xref>
###xml 409 412 409 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Beers1">[8]</xref>
###xml 413 417 413 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Wu1">[12]</xref>
###xml 525 529 525 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Baba1">[13]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Bas1">[14]</xref>
###xml 562 566 562 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Casal1">[15]</xref>
###xml 567 571 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Shalit1">[17]</xref>
###xml 601 605 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-BarOr1">[18]</xref>
###xml 607 611 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Filion1">[19]</xref>
###xml 763 767 763 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Aharoni1">[20]</xref>
###xml 768 772 768 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Schori1">[30]</xref>
###xml 969 972 969 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-McGeer1">[6]</xref>
###xml 974 978 974 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Alexianu1">[31]</xref>
###xml 979 983 979 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Troost1">[36]</xref>
###xml 1075 1079 1075 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Angelov1">[37]</xref>
###xml 1080 1084 1080 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Haenggeli1">[39]</xref>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 143 148 <span type="species:ncbi:9606">human</span>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
###xml 399 404 <span type="species:ncbi:9606">human</span>
###xml 926 931 <span type="species:ncbi:10090">mouse</span>
###xml 1070 1074 <span type="species:ncbi:10090">mice</span>
###xml 1171 1175 <span type="species:ncbi:10090">mice</span>
Innate immune dysfunction is a pathogenic feature of amyotrophic lateral sclerosis (ALS) [1], [2]. Transgenic (Tg) mice overexpressing mutated human G93A superoxide dismutase 1 (SOD1) [3] recapitulate ALS pathobiology including neuroinflammatory responses and motor neuron degeneration [4]-[7]. Microglial inflammatory responses contribute to progressive neuronal loss in SOD1 mutant Tg mice and in human ALS [8]-[12]. Functional ties between adaptive immunity and neurodegenerative disease are known for Parkinson's disease [13], [14], Alzheimer's disease (AD) [15]-[17], and multiple sclerosis (MS) [18], [19]. Moreover, neuroprotective responses by Copolymer-1 (COP-1) immunization were observed in animal models of these and other neurodegenerative disorders [20]-[30]. However, links between adaptive immunity and ALS remains obscure. Changes in T cell numbers and adaptive immune molecules in postmortem ALS and SOD1 Tg mouse nervous system tissues were reported [6], [31]-[36]. Interestingly, such COP-1 immunization strategies yielded mixed results in G93A-SOD1 mice [37]-[39]. Taken together, these findings suggest a progressive immune dysfunction in G93A-SOD1 mice.
###end p 9
###begin p 10
###xml 190 193 190 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Beers1">[8]</xref>
###xml 195 199 195 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Xiao1">[40]</xref>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Zhang1">[41]</xref>
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Zhang2">[42]</xref>
###xml 448 452 448 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Alexianu1">[31]</xref>
###xml 454 458 454 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Xiao1">[40]</xref>
###xml 460 464 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Zhang1">[41]</xref>
###xml 466 470 466 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Zhao1">[43]</xref>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 179 184 <span type="species:ncbi:9606">human</span>
###xml 201 206 <span type="species:ncbi:9606">Human</span>
Mutant SOD1 may play a role in progression of ALS as microglia recovered from G93A-SOD1 mice induce increased motoneuron injury than microglia from over-expressing wild-type (Wt) human SOD1 [8], [40]. Human ALS immunocytes show that both activated monocytes and T cell numbers are linked to disease progression [41], [42]. These data are consistent with a disease model where systemic immunologic activation plays an active role in ALS progression [31], [40], [41], [43].
###end p 10
###begin p 11
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Habisch1">[38]</xref>
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Haenggeli1">[39]</xref>
###xml 671 675 671 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Benner1">[23]</xref>
###xml 677 681 677 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Laurie1">[28]</xref>
###xml 683 687 683 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Reynolds1">[44]</xref>
###xml 721 722 721 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 726 727 726 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 739 740 739 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 744 745 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 462 466 <span type="species:ncbi:10090">mice</span>
###xml 488 492 <span type="species:ncbi:10090">mice</span>
###xml 844 848 <span type="species:ncbi:10090">mice</span>
###xml 1118 1123 <span type="species:ncbi:9606">human</span>
Based on these observations, we investigated T cell phenotype and function in G93A-SOD1 Tg mice and in ALS patients. In support of our own observations and those made by others [38], [39] COP-1 immunization provided clinical benefit to only female G93A-SOD1 Tg mice. We observed profound T cell functional deficits in pre-symptomatic male G93A-SOD1 Tg mice spleen as well as acute lymphopenia in end stage animals. Transfer of naive lymphoid cells from Wt donor mice to SOD1 Tg recipient mice failed to affect survival or overcome the observed lymphopenia. As COP-1 is linked to neuroprotective T regulatory cells (Treg) and the modulation of neuroinflammatory responses [23], [28], [44], we next investigated whether CD4+CD25+ Treg or CD4+CD25- T effector cells (Teff) could affect neurological deficits and survival. Importantly, for SOD1 Tg mice, polyclonal-activated Wt Treg or Teff administered by adoptive transfer extended longevity and attenuated motor deficits. Treg delayed clinical symptom onset, while Teff increased latency from onset to late stage disease. These results together with supportive data in human ALS suggest the presence of aberrant T cell subsets in disease.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
Animals
###end title 13
###begin p 14
###xml 236 239 236 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Gurney1">[4]</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 22 27 <span type="species:ncbi:10090">mouse</span>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
###xml 399 403 <span type="species:ncbi:10090">mice</span>
###xml 454 458 <span type="species:ncbi:10090">Mice</span>
Mice from two SOD1 Tg mouse strains expressing the G93A mutation, B6SJL-TgN(SOD1*G93A)1Gur (stock number, 002726; hereafter designated B6SJL SOD1 Tg) and B6.Cg-Tg(SOD1*G93A)1Gur/J (stock number, 004435; hereafter designated B6 SOD1 Tg) [4], and age- and sex-matched Wt littermates were obtained from Jackson Laboratory (Bar Harbor, ME). B6SJL SOD1 Tg mice survive from 16-20 weeks, while B6 SOD1 Tg mice have a delayed survival phenotype of 19-22 weeks. Mice were randomly separated to control and treatment groups upon receipt. All animal procedures met with National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Nebraska Medical Center.
###end p 14
###begin title 15
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Subjects
###end title 15
###begin p 16
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 166 171 <span type="species:ncbi:9606">Human</span>
Experimental procedures involving human subjects were conducted in conformance with the policies and principles contained in the Federal Policy for the Protection of Human Subjects (U.S. Office of Science and Technology Policy) and in the Declaration of Helsinki.
###end p 16
###begin title 17
COP-1 Immunization
###end title 17
###begin p 18
###xml 11 15 <span type="species:ncbi:10090">mice</span>
B6 SOD1 Tg mice (7 weeks old) were immunized with 75 microg of COP-1 in 0.1 ml PBS weekly (q1wk) or every 2 weeks (q2wk), or treated with PBS alone. Subcutaneous injections were administered in the flanks with a 50 microl bolus given to each side.
###end p 18
###begin title 19
Spleen Morphology, Weight, Viable Cell Counts
###end title 19
###begin p 20
###xml 23 27 <span type="species:ncbi:10090">mice</span>
Spleens from Wt and Tg mice were measured and weighed. Single cell suspensions were prepared by pressing spleens through 60 microm sterile wire mesh screens in Hanks' balanced salt solution (HBSS, Mediatech Inc., Herndon, VA). Erythrocytes were lysed with ammonium chloride potassium buffer and leukocytes washed by centrifugation. Numbers of viable splenic leukocytes were determined by trypan blue exclusion of hemocytometer counts.
###end p 20
###begin title 21
Lymphocyte Proliferation
###end title 21
###begin p 22
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 604 605 586 587 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 893 894 863 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 920 921 890 891 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 166 172 <span type="species:ncbi:9913">bovine</span>
###xml 484 488 <span type="species:ncbi:9925">goat</span>
###xml 626 630 <span type="species:ncbi:10090">mice</span>
Splenocytes from individual animals were plated in 96-well round-bottom plates at 1x106 cell/ml in RPMI medium 1640 (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 25 mM HEPES, 1 mM sodium pyruvate, 1x nonessential amino acids, 55 mM 2-mercaptoethanol, 100 units/ml penicillin, and 100 microg/ml streptomycin (complete RPMI 1640) (Mediatech Inc.). Quadruplicate replicates were stimulated with anti-CD3 (1 microg/ml) (clone 145-2C11, BD Pharmingen), goat anti-IgM (20 microg/ml) (Jackson Immuno Research, West Grove, PA) or cultured in media alone at 37degreesC in 5% CO2 for 3 days. From Tg mice immunized with COP-1 (Sigma-Aldrich, St. Louis, MO), spleen cells were cultured in the presence of COP-1 (5 microg/ml), concanavalin A (Con A, 2 microg/ml, Sigma-Aldrich), or media for 5 days. Cells were pulsed for the final 18 hrs of incubation with 1 microCi [3H] methylated thymidine ([3H]-TdR) (MP Biomedicals ICN, Solon, OH), harvested onto glass-fiber filters, and counted by beta-scintillation spectrometry (Top Count, Packard Instrument Co., Meriden, CT). Levels of spleen cell proliferation for each animal were normalized to levels of proliferation obtained from cells cultured in media alone and were reported as a stimulation index.
###end p 22
###begin title 23
Immunohistochemical Assays
###end title 23
###begin p 24
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 500 506 <span type="species:ncbi:9986">rabbit</span>
###xml 962 968 <span type="species:ncbi:9986">rabbit</span>
###xml 974 977 <span type="species:ncbi:10116">rat</span>
###xml 1060 1071 <span type="species:ncbi:3704">horseradish</span>
Fresh frozen spleens of Tg mice and Wt littermates were embedded in OCT media (Sakura Fintek, Torrance, CA) and sectioned at 10 microm using a cryostat (CM1900, Leica, Bannockburn, IL). Sections were collected on slides and fixed in ice-cold acetone-methanol (1:1) for 30 min. Slides were washed in phosphate-buffered saline (PBS) at room temperature (RT) and quenched for endogenous peroxidase activity in 3% hydrogen peroxide in methanol for 15 min. Nonspecific staining was blocked with 5% normal rabbit serum (NRS) (Vector Laboratories, Burlingame, CA) in PBS for 1 hr. For immunostaining, primary antibodies (clone designations and dilutions) included anti-CD3 (clone 17A2, 1:100), anti-CD19 (clone 1D3, 1:100), anti-F4/80 (clone BM8, 1:500) and anti-Gr-1 (clone RB6-8C5, 1:100) (all obtained from eBioscience, San Diego, CA). Sections were incubated with primary antibody diluted in PBS/5% NRS for 90 min at RT, washed in PBS and incubated with polyclonal rabbit anti-rat immunoglobulin (1:400) (Dako, Capinteria, CA) for 30 min followed by streptavidin-horseradish peroxidase solution (ABC Elite vector kit, Vector Laboratories) for 30 min. Staining was visualized by addition of hydrogen peroxide substrate and diaminobenzidine chromogen (DAB substrate kit for peroxidase, Vector Laboratories) solution. Sections were counterstained with hematoxylin (Surgipath Medical Industries, Inc., Richmond, IL), dehydrated, covered with mounting media (Cytoseal 60, Kalamazoo, MI) and mounted with a glass coverslip. Slides were examined under a light microscope (Eclipse E800, Nikon, Inc., Melville, NY) and representative images captured at 100x magnification. Follicle counts, area per follicle, and densities of CD3, CD19, F4/80 and Gr-1 expression were evaluated from 4 fields/animal by digital image analysis using Image-Pro Plus version 4 software (Media Cybernetics, Silver Spring, MD).
###end p 24
###begin title 25
###xml 34 39 <span type="species:ncbi:10090">Mouse</span>
###xml 44 49 <span type="species:ncbi:9606">Human</span>
Flow Cytometric (FCM) Analysis of Mouse and Human Leukocytes
###end title 25
###begin p 26
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Single cell suspensions of spleens from Wt and Tg mice were stained with fluorescein isothiocyanate (FITC)-conjugated (clone designate) anti-CD19 (1D3), anti-CD4 (RM4-4), anti-CD62L (Mel-14), and anti-Gr-1 (RB6-8C5); phycoerythrin (PE)-conjugated (clone) anti-CD4 (GK1.5), anti-CD8b (53-5.8), and F4/80 (BM8, eBioscience); and allophycocyanin (APC)-conjugated (clone) anti-CD3 (145-2C11) and anti-CD44 (1M7). All antibodies except where indicated were obtained from BD Pharmingen (San Diego, CA).
###end p 26
###begin p 27
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 336 343 <span type="species:ncbi:9606">patient</span>
Peripheral blood from 10 ALS patients and their age-matched caregivers were collected in ethylenediaminetetraacetic acid (EDTA) containing glass tubes at Columbia University, shipped overnight, and processed upon arrival at the University Nebraska Medical Center. Complete blood count (CBC) and differential analysis for each donor and patient were determined from samples obtained prior to shipping. For FCM analysis, 20 microl of appropriate fluorochrome-conjugated antibodies were added to 100 microl of whole blood and incubated in the dark for 30 min at RT. Erythrocytes were lysed and leukocytes fixed with FACS Lysing solution (BD Biosciences). Antibodies (clone) utilized in these studies included FITC-conjugated anti-CD8a (RPA-T8), anti-CD16 (55661), anti-CD45RA (HI1100), and anti-CD19 (H1B19); PE-conjugated anti-CD14 (55715) and anti-CD4 (OKT4); and APC-conjugated anti-CD3 (UCHT1), anti-HLA-DR (LN3), and anti-CD45R0 (UCHL1).
###end p 27
###begin p 28
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
###xml 18 23 <span type="species:ncbi:9606">human</span>
Stained mouse and human leukocytes were evaluated by FCM analysis using a FACSCalibur flow cytometer interfaced with CellQuest software (BD-Biosciences, Immunocytometry Systems). Electronic bit maps were utilized to encompass and gate lymphocyte and monocyte subsets during FCM analysis.
###end p 28
###begin title 29
Measures of Lymphocyte Apoptosis and Necrosis
###end title 29
###begin p 30
###xml 540 541 540 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 546 547 546 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 579 580 579 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 585 586 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Spleen cells from 14 weeks old Wt and Tg mice were evaluated as fresh isolates or were stimulated for 24 or 48 hrs as for lymphocyte proliferation. Harvested spleen cells were stained with annexin-V-FITC (Apoptosis Detection kit, Calbiochem/EMD Biosciences, Inc., San Diego, CA), PE-anti-Thy-1 (clone 53-2.1) to detect T cells, and APC anti-CD45R/B220 (clone RA3-6B2) to detect B cells (eBioscience). Actinomycin D (7-ADD; BD Pharmingen) was used as a viable exclusion indicator for membrane permeability to distinguish apoptotic (annexin-V+7-ADD-) from necrotic cells (annexin-V+7-ADD+), the latter having lost membrane integrity.
###end p 30
###begin title 31
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
Isolation and Purification of CD4+CD25+ (Treg) and CD4+CD25- (Teff) Cells
###end title 31
###begin p 32
###xml 58 62 58 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Reynolds1">[44]</xref>
###xml 300 301 300 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 352 353 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 393 394 393 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 468 469 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 519 520 519 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 810 811 810 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 815 816 815 816 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 893 894 893 894 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 898 899 898 899 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1203 1204 1203 1204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1208 1209 1208 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1214 1215 1214 1215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1240 1241 1240 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1245 1246 1245 1246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1251 1252 1251 1252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1371 1372 1371 1372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1470 1471 1466 1467 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1512 1513 1508 1509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1517 1518 1513 1514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1615 1619 1611 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Reynolds1">[44]</xref>
###xml 1637 1638 1633 1634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1642 1643 1638 1639 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
###xml 1564 1569 <span type="species:ncbi:10090">mouse</span>
Treg and Teff cells were isolated as previously described [44]. Lymph nodes (cervical, mandibular, axillary, brachial, inguinal and mesenteric) and spleens were harvested from male Wt B6 mice (9 weeks old). After lysis of red blood cells, T cell populations were enriched by negative selection on CD3+ T cell columns (R&D Systems, Minneapolis, MN). CD3+ T cells were further passed through CD4+ T cell subset enrichment column (R&D Systems) to obtain a highly pure CD4+ T cell population in the eluted fraction. The CD4+ T cell fraction was incubated with PE-labeled anti-CD25 antibody (BD Pharmingen) followed by anti-PE microbeads (Miltenyi Biotec, Auburn, CA) and subjected to magnetic separation (Auto MACS, Miltenyi Biotec). Nonadherent cells were eluted from the magnetic column and were enriched for CD4+CD25- Teff cells, while adherent cells eluted from the column were enriched as CD4+CD25+ Treg cells. Purity of nonadherent and adherent cell fractions were determined by FCM analysis (FACSCalibur flow cytometer, BD Biosciences) using antibodies that recognize disparate epitopes to CD3, CD19, CD4, CD8, CD25, and Foxp3 (eBioscience). Prior to activation, fresh isolates of Tregs were >95% CD4+CD25+Foxp3+ while Teff were >95% CD4+CD25-Foxp3-. To activate and expand enriched T cell populations, purified cells were cultured for 4 days in 24-well plates at 1x106 cells per ml of complete RPMI 1640 with 0.5 microg/ml anti-CD3 (145-2C11; BD Pharmingen) and 3x106 irradiated splenocytes (3,300 rads). CD4+CD25+ T cells required the addition of 100 U/ml of mouse recombinant interleukin (IL)-2 (R&D Systems) [44]. Furthermore, CD4+CD25+ Tregs exhibited increased expression of mRNA for Foxp3, TGF-beta and IL-10, whereas Teff showed increased expression of IFN-gamma mRNA. Tregs also inhibited anti-CD3 induced mitogenesis in a dose-dependent manner (data not shown).
###end p 32
###begin title 33
Adoptive Cell Transfers
###end title 33
###begin p 34
###xml 147 155 147 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 240 241 240 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 261 262 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
Freshly isolated lymphocytes obtained from spleens of naive Wt B6 donor mice and anti-CD3 activated Treg or Teff cells after 4 days of stimulation in vitro were harvested, washed, and resuspended in HBSS. To B6 SOD1 Tg recipient mice, 50x106 lymphocytes or 1x106 Treg or Teff cells in 0.25 ml of HBSS or PBS alone were administered intravenous every 6 weeks at 7, 13, and 19 weeks of age.
###end p 34
###begin title 35
Body Weight and Clinical Signs
###end title 35
###begin p 36
###xml 625 629 625 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Weydt1">[45]</xref>
###xml 719 723 <span type="species:ncbi:10090">Mice</span>
The initial sign of the disease is a high frequency resting tremor that progresses to gait impairment, asymmetrical or symmetrical paralysis of the hind limbs, followed by complete paralysis at end stage. Beginning at 7 weeks of age, all animals were assessed weekly for body weight and for signs of motor deficit with the following 4 point-scoring system: 4 points if normal (no sign of motor dysfunction), 3 points if hind limb tremors were evident when suspended by the tail, 2 points if gait abnormalities were present, 1 point for dragging of at least one hind limb, and 0 point for symmetrical paralysis [modified from [45]. Disease onset was determined at the earliest presentation of symptoms (i.e. score = 3). Mice that reached a clinical score of 0 or lost 20% of maximum body weight were deemed unable to survive, removed from the study, immediately euthanized, and scored as a terminal event.
###end p 36
###begin title 37
Paw Grip Endurance (PaGE) Test
###end title 37
###begin p 38
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Weydt1">[45]</xref>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 95 100 <span type="species:ncbi:10090">mouse</span>
###xml 191 196 <span type="species:ncbi:10090">mouse</span>
###xml 290 295 <span type="species:ncbi:10090">mouse</span>
###xml 327 332 <span type="species:ncbi:10090">mouse</span>
Grip strength of hind limbs of mice were assessed each week as previously described [45]. Each mouse was placed on the wire-lid of a conventional housing cage and gently shaken to prompt the mouse to hold on to the grid. The lid was turned upside down and the duration determined until the mouse released both hind limbs. Each mouse was given three attempts with a maximum duration of 90 sec and the longest latency was recorded.
###end p 38
###begin title 39
Rotarod Performance
###end title 39
###begin p 40
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Haenggeli1">[39]</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
Mice were pre-conditioned for 3 days prior to testing then monitored for rotarod performance once every week starting at 7 weeks of age [39]. In brief, mice were placed on a partitioned rotating rod (Rotamex Rota-rod apparatus, Columbus Instruments, Columbus, OH) and tested at a 5, 10, and 15 rpm for a maximum of 90 sec at each speed with a minimum of 5 min rest between attempts. The overall rotarod performance (ORP) was calculated as the area under the curve using Prism (version 4, Graphpad Software, San Diego, CA) from the plot of the time that the animal remained on the rod as a function of the rotation speed
###end p 40
###begin title 41
Statistical Analyses
###end title 41
###begin p 42
###xml 113 114 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 202 210 200 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 312 320 310 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
All values are expressed as mean+/-SEM. Differences among normally distributed means were evaluated by Student's t test for two group comparisons or one-way ANOVA followed by Bonferroni or Fisher's LSD post-hoc tests for pairwise comparisons amongst multiple data sets exhibiting equal variances or by Dunnett's post-hoc tests for data exhibiting unequal variances (Statistica v7, StatSoft, Tulsa, OK, and SPSS v13, SPSS, Inc., Chicago, IL). Cox's F-test comparison was performed for comparison between treatment groups for Kaplan-Meier analyses.
###end p 42
###begin title 43
Results
###end title 43
###begin title 44
###xml 33 37 <span type="species:ncbi:10090">Mice</span>
COP-1 Immunization of B6 SOD1 Tg Mice
###end title 44
###begin p 45
###xml 557 564 553 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g001">Fig. 1A</xref>
###xml 1159 1166 1155 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g001">Fig. 1B</xref>
###xml 1379 1386 1375 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g001">Fig. 1C</xref>
###xml 1654 1661 1650 1657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g001">Fig. 1D</xref>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 571 575 <span type="species:ncbi:10090">mice</span>
###xml 1085 1089 <span type="species:ncbi:10090">mice</span>
###xml 1202 1206 <span type="species:ncbi:10090">mice</span>
###xml 1313 1317 <span type="species:ncbi:10090">mice</span>
###xml 1373 1377 <span type="species:ncbi:10090">mice</span>
###xml 1532 1536 <span type="species:ncbi:10090">mice</span>
###xml 1648 1652 <span type="species:ncbi:10090">mice</span>
###xml 1777 1781 <span type="species:ncbi:10090">mice</span>
Our initial works investigated whether COP-1 immunization of B6 SOD1 Tg mice affect disease progression. In these experiments we immunized male and female B6 SOD1 Tg mice with 75 microg COP-1 s.c. in 0.1 ml PBS either every week (q1wk) or every other week (q2wk), or animals were treated every week with PBS as excipient controls. Kaplan-Meier analysis indicated that weekly COP-1 immunization had an affect on the lifespan of SOD1 Tg mice compared to PBS controls (p = 0.0413), however immunization every other week did not increase survival (p = 0.1673) (Fig. 1A). For mice immunized weekly with COP-1, the mean age of survival increased by 9.9% compared to PBS controls (p = 0.006), while COP-1 immunization every other week increased the mean age of survival by 6.1%, however this did not reach significance (data not shown). Log-normal analysis of mortality probability at 10 day intervals showed that COP-1 immunization every week and every other week initially provided protective benefits compared to PBS controls; however, by 160 days of age, the probability of mortality for mice immunized every other week evolved to that afforded by PBS controls (Fig. 1B). Kaplan-Meier analysis of treated mice stratified for gender indicated that increased survival by weekly immunization was associated with female mice (p = 0.0434), but had no effect on survival of male Tg mice (Fig. 1C). Similarly, compared to PBS treated controls, immunization with COP-1 every week increased the mean age of survival for female, but not male Tg mice, and immunization every other week produced no difference in mean age of survival for either male or female Tg mice (Fig. 1D). These results posed the question as to whether adaptive immunity was fully functional in pre-symptomatic SOD1 Tg mice.
###end p 45
###begin title 46
###xml 40 44 <span type="species:ncbi:10090">mice</span>
Effect of COP-1 immunization in B6 SOD1 mice.
###end title 46
###begin p 47
###xml 1128 1129 1126 1127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 1181 1189 1179 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 1392 1393 1382 1383 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1976 1977 1961 1962 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 2047 2048 2032 2033 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
###xml 489 493 <span type="species:ncbi:10090">mice</span>
###xml 604 608 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
###xml 743 747 <span type="species:ncbi:10090">mice</span>
###xml 878 882 <span type="species:ncbi:10090">mice</span>
###xml 1072 1076 <span type="species:ncbi:10090">mice</span>
###xml 1160 1164 <span type="species:ncbi:10090">mice</span>
###xml 1221 1225 <span type="species:ncbi:10090">mice</span>
###xml 1830 1834 <span type="species:ncbi:10090">mice</span>
Mice were treated with PBS (closed circles and black bars), COP-1 weekly (q1wk) (open boxes and gray bars), or COP-1 every 2 weeks (q2wk) (open triangles and white bars). (A) Kaplan-Meier analysis of the proportion of surviving SOD1 Tg mice as a function of age. Cox's F-test comparison showed groups treated with PBS vs COP-1 q1wk (p = 0.0413) or COP-1 q2wk (p = 0.1151), and COP-1 q1wk vs COP-1 q2wk (p = 0.1673). (B) Log-normal analysis of mortality probability at 10 day intervals for mice treated with PBS, COP-1 q1wk, COP-1 q2wk. (C) Kaplan-Meier plot of the proportion of surviving female SOD1 Tg mice (left panel) or male SOD1 Tg mice (right panel) as a function of age showing the gender effect. Cox's F-test comparison showed female mice groups treated with PBS vs COP-1 q1wk (p = 0.0434) or COP-1 q2wk (p = 0.2449), and COP-1 q1wk vs COP-1 q2wk (p = 0.0846) and male mice groups treated with PBS vs COP-1 q1wk (p = 0.4240) or COP-1 q2wk (p = 0.1615), and COP-1 q1wk vs COP-1 q2wk (p = 0.1430). (D) Mean age of survival+/-SEM for 7-10 female or 5-6 male SOD1 Tg mice/group treated with PBS, COP-1 q1wk, or COP-1 q2wk. aP<0.05 compared to PBS treated mice with Bonferroni post-hoc tests. Spleen cells from B6 Tg mice treated with PBS, COP-1 q1wk, or COP-1 q2wk were stimulated with (E) Cop-1 (5 microg/ml), (F) Con A (2 microg/ml) or cultured in media alone. Cells were pulsed with [3H]-TdR for the final 18 hrs of culture, harvested onto glass fiber filters and counted by beta-scintillation spectrometry. Counts were normalized as a ratio of those obtained from culture in media alone to generate a stimulation index for spleen cell proliferation from each animal. A stimulation index of 1 is defined by spleen cells cultured in media alone (dashed line). Means of stimulation indices (+/-SEM) were determined from 4-5 mice/group for (E) antigen-specific proliferation elicited by Cop-1 and (F) polyclonal T cell proliferation induced by the T cell mitogen, Con A. aP<0.05, above media control (stimulation index = 1, dashed line); and bP<0.05 compared to weeks 4 or 8 within each treatment group.
###end p 47
###begin title 48
###xml 44 48 <span type="species:ncbi:10090">Mice</span>
Impaired T Cell Immune Responses in SOD1 Tg Mice
###end title 48
###begin p 49
###xml 431 439 431 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 617 624 617 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g001">Fig. 1E</xref>
###xml 1374 1381 1374 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g001">Fig. 1F</xref>
###xml 1853 1854 1853 1854 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 316 320 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 579 583 <span type="species:ncbi:10090">mice</span>
###xml 1003 1007 <span type="species:ncbi:10090">mice</span>
###xml 1228 1232 <span type="species:ncbi:10090">mice</span>
###xml 1442 1446 <span type="species:ncbi:10090">mice</span>
###xml 1462 1466 <span type="species:ncbi:10090">mice</span>
###xml 1846 1850 <span type="species:ncbi:10090">mice</span>
###xml 1976 1980 <span type="species:ncbi:10090">mice</span>
Based on the failure of the COP-1 immunization strategies to increase longevity in male SOD1 Tg mice, and preliminary data showing diminished spleen size and immune responses with age, we tested whether T cell responses were functional. These studies revealed that T cell immune function elicited in B6 SOD1 Tg male mice was significantly impaired by 19 weeks of age. Spleen cells from 4 and 8 week-immune SOD1 Tg mice, stimulated in vitro with COP-1 exhibited increased stimulation indices compared to those cultured in media alone (dashed line), whereas cells from PBS treated mice were unable to respond to COP-1 (Fig. 1E) indicating that immunization strategies elicited functional COP-1 responsive T cells in early stage of the disease. However, after 12 weeks of weekly or bi-weekly immunizations, stimulation indices of COP-1 stimulated spleen cells diminished to levels statistically indiscernible from those of cells cultured in media alone indicating that the T cell immune responses in those mice had waned. In concomitant assays to test the overall functionality of all T cell populations, we stimulated spleen cell cultures with Con A, a T cell mitogen. Stimulation indices of Con A induced T cells from B6 SOD1 Tg mice in all treatment groups after 4 and 8 weeks (at 11 and 15 weeks of age) were significantly above those of media control cells (dashed line) (Fig. 1F), demonstrating the presence of functional T cells in those mice. However in Tg mice at 19 weeks of age, after 12 weeks of treatment, stimulation indices of Con A stimulated T cells were indistinguishable from those cultured in media alone. Regression analysis of stimulation indices of Con A stimulated T cells from PBS controls indicated a progressively diminished proliferative capacity of T cells that was strongly associated with increasing age of B6 SOD1 Tg mice (r2 = 0.6308, p = 0.002). Taken together these results suggest a global dysregulation of T cell function with age in SOD1 Tg mice.
###end p 49
###begin title 50
###xml 47 51 <span type="species:ncbi:10090">Mice</span>
Spleen Size, Weight and Cell Counts in SOD1 Tg Mice
###end title 50
###begin p 51
###xml 528 547 528 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g002">Fig. 2A, left panel</xref>
###xml 641 661 641 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g002">Fig. 2A, right panel</xref>
###xml 920 927 920 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g002">Fig. 2B</xref>
###xml 1298 1305 1298 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g002">Fig. 2C</xref>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 483 487 <span type="species:ncbi:10090">mice</span>
###xml 582 586 <span type="species:ncbi:10090">mice</span>
###xml 751 755 <span type="species:ncbi:10090">mice</span>
###xml 859 863 <span type="species:ncbi:10090">mice</span>
###xml 899 903 <span type="species:ncbi:10090">mice</span>
###xml 1046 1050 <span type="species:ncbi:10090">mice</span>
###xml 1100 1104 <span type="species:ncbi:10090">mice</span>
###xml 1265 1269 <span type="species:ncbi:10090">mice</span>
Based on marginal protection achieved by COP-1 immunization and progressively diminished T cell function with age, we next investigated the adaptive immune system in disease whereby spleens from B6SJL G93A-SOD1 Tg mice were compared at early symptomatic stage (14 weeks of age) and end stage (20-22 weeks of age) with those of age and sex-matched Wt littermate controls. All Tg mice at 14 weeks of age exhibited hind limb tremors. Morphologically, spleens from 14 weeks old B6SJL Tg mice were identical to those of Wt controls (Fig. 2A, left panel), whereas, spleens from end stage mice showed marked reduction in size compared to controls (Fig. 2A, right panel). Similarly, no differences in spleen weights from pre-symptomatic and symptomatic B6SJL mice compared to Wt were discerned, whereas at end stage, spleen weights were diminished by 45% in B6SJL Tg mice (19 weeks old) and by 59% in B6 Tg mice (22 weeks old) (Fig. 2B). No differences in gross morphology or weights for non-lymphoid kidneys or livers were discernible between Tg and Wt mice at any age (data not shown). For end stage B6 Tg mice, total viable spleen cell numbers were diminished by 70% compared to Wt controls, whereas no differences in spleen cell numbers were observed between Tg and Wt mice in early symptomatic stage (Fig. 2C).
###end p 51
###begin title 52
###xml 31 35 <span type="species:ncbi:10090">mice</span>
Spleen changes in G93A-SOD1 Tg mice.
###end title 52
###begin p 53
###xml 54 58 <span type="species:ncbi:10090">mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 294 298 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
(A) Morphology and size of spleens from B6SJL SOD1 Tg mice and Wt littermates at 14 weeks of age (left panel) and 20 weeks of age (right panel). (B) Mean spleen weights were compared between B6SJL Wt littermates and B6SJL SOD1 Tg mice at 7, 16 and 19 weeks age and between B6 Wt and B6 SOD1 Tg mice at 22 weeks age (n = 5-9 mice/group). (C) Total spleen cell numbers were compared between Wt littermates and B6SJL SOD1 Tg mice at 14 and 22 weeks of age. Values are means+/-SEM for 3-9 mice per group.
###end p 53
###begin title 54
###xml 34 38 <span type="species:ncbi:10090">Mice</span>
Immune Tissue Analyses of SOD1 Tg Mice
###end title 54
###begin p 55
###xml 541 564 541 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g003">Fig. 3B, 3E, 3H, and 3K</xref>
###xml 585 608 585 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g003">Fig. 3C, 3F, 3I, and 3L</xref>
###xml 640 663 640 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g003">Fig. 3A, 3D, 3G, and 3J</xref>
###xml 684 685 684 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 737 744 737 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g003">Fig. 3B</xref>
###xml 759 766 759 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g003">Fig. 3C</xref>
###xml 794 801 794 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g003">Fig. 3A</xref>
###xml 831 850 831 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g003">Fig. 3D, 3E, and 3F</xref>
###xml 862 881 862 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g003">Fig. 3G, 3H, and 3I</xref>
###xml 1039 1053 1039 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g003">Fig. 3K and 3L</xref>
###xml 1100 1107 1100 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g003">Fig. 3J</xref>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
###xml 149 153 <span type="species:ncbi:10090">mice</span>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 610 614 <span type="species:ncbi:10090">mice</span>
###xml 768 772 <span type="species:ncbi:10090">mice</span>
###xml 788 792 <span type="species:ncbi:10090">mice</span>
###xml 950 954 <span type="species:ncbi:10090">mice</span>
###xml 1033 1037 <span type="species:ncbi:10090">mice</span>
To assess splenic architecture in end stage mice, we assessed expression of CD3, CD19, F4/80, and Gr-1 in fresh frozen sections from end stage B6 Tg mice (22 weeks old), B6SJL Tg mice (19 weeks old), and age-matched Wt controls. Splenic architecture in end stage B6 Tg and B6SJL Tg mice revealed remarkable alterations in follicle number, size, and expression of hematopoietic lineage markers compared to Wt B6 littermates. Splenic follicular architecture appeared diminished with a greater number of follicles in each field for B6 SOD1 Tg (Fig. 3B, 3E, 3H, and 3K) and B6SJL SOD1 Tg (Fig. 3C, 3F, 3I, and 3L) mice compared to Wt controls (Fig. 3A, 3D, 3G, and 3J). The density of CD3+ T cells in the spleen appeared unaltered in B6 Tg (Fig. 3B) or B6SJL Tg (Fig. 3C) mice compared to Wt mice (Fig. 3A), while expression of F/480 (Fig. 3D, 3E, and 3F) and Gr-1 (Fig. 3G, 3H, and 3I) in the perifollicular area of spleen appeared increased in SOD1 Tg mice and the density of CD19 expression by B cells within the follicles of SOD1 Tg mice (Fig. 3K and 3L) appeared diminished compared to Wt controls (Fig. 3J) .
###end p 55
###begin title 56
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Altered spleen architecture from end stage G93A-SOD1 Tg mice.
###end title 56
###begin p 57
###xml 559 560 559 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 162 166 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 331 335 <span type="species:ncbi:10090">mice</span>
Representative photomicrographs of immunohistochemistry are shown for expression of CD3, F4/80, Gr-1, CD19 of fresh frozen spleen sections from end stage SOD1 Tg mice and age-matched Wt controls. Photomicrographs in the left panels are from B6 Wt mice, while middle and right panels show sections from B6 SOD1 Tg and B6SJL SOD1 Tg mice, respectively. Sections are stained by immunoperoxidase (brown) for expression of (A, B, C) CD3 by T cells; (D, E, F) F4/80 by perifollicular macrophages; (G, H, I) Gr-1 immunoreactivity on myeloid cells; and (J, K, L) CD19+ on B cells. Sections are counterstained with hematoxylin (blue).
###end p 57
###begin p 58
###xml 149 156 149 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g004">Fig. 4A</xref>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 210 217 210 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g004">Fig. 4B</xref>
###xml 354 361 354 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g004">Fig. 4C</xref>
###xml 483 490 483 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g004">Fig. 4D</xref>
###xml 549 556 549 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g004">Fig. 4E</xref>
###xml 635 642 635 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g004">Fig. 4F</xref>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 348 352 <span type="species:ncbi:10090">mice</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
These observations were validated by digital image analysis in B6 Wt and B6 SOD1 Tg mice. In Tg mice, splenic follicular area was diminished by 67% (Fig. 4A) and numbers of follicles/mm2 were increased by 41% (Fig. 4B) compared to Wt controls. No difference in the densities of splenic CD3 expression could be ascertained between Tg and Wt control mice (Fig. 4C). In the splenic perifollicular area of Tg mice compared to Wt controls, the mean density of F4/80 was increased by 47% (Fig. 4D), density of Gr-1 expressing cells was increased by 165% (Fig. 4E), while the intrafollicular density of CD19 expression was diminished by 88% (Fig. 4F).
###end p 58
###begin title 59
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Comparison of spleen architecture between Wt and SOD1 B6 Tg mice (22 weeks old).
###end title 59
###begin p 60
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 200 201 200 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 220 221 220 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 243 244 243 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 264 265 264 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 172 177 <span type="species:ncbi:10090">mouse</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
(A) Mean area/follicle and (B) mean numbers of follicles/mm2 were determined for B6 Wt and B6 SOD1 Tg mice from digital images taken at 100x magnification (4 random fields/mouse). Densities of (C) CD3+ T cells, (D) F4/80+ macrophages, (E) Gr-1+ cells, and (F) CD19+ B cells from concomitantly stained sections were determined by digital image analysis from 100x magnifications using Image-Pro Plus software. Values are means+/-SEM for 3-6 mice per group.
###end p 60
###begin title 61
###xml 69 73 <span type="species:ncbi:10090">Mice</span>
Impaired Lymphocyte Proliferation and Necrosis in Spleens of SOD1 Tg Mice
###end title 61
###begin p 62
###xml 333 334 333 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 362 369 362 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g005">Fig. 5A</xref>
###xml 414 415 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 419 421 419 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 426 428 426 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 478 479 478 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 483 485 483 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 490 492 490 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 583 584 583 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 629 636 629 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g005">Fig. 5B</xref>
###xml 702 703 702 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 708 709 708 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 734 735 734 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 740 741 740 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 782 783 782 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 808 809 808 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1021 1022 1021 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1027 1028 1027 1028 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1103 1104 1103 1104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1109 1110 1109 1110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1157 1164 1157 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g005">Fig. 5C</xref>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 522 526 <span type="species:ncbi:10090">mice</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
###xml 887 891 <span type="species:ncbi:10090">mice</span>
###xml 951 955 <span type="species:ncbi:10090">mice</span>
###xml 1257 1261 <span type="species:ncbi:10090">mice</span>
###xml 1282 1286 <span type="species:ncbi:10090">mice</span>
Based on diminished T cell responses and observations of profound lymphopenia in G93A-SOD1 Tg mice at end stage, we assessed splenic lymphocyte phenotype and function in early symptomatic (14 weeks old) B6SJL SOD1 Tg mice to detect early immune cell aberrations in spleen. Flow cytometric analysis of CD62L and CD44 expression on CD4+ gated splenic lymphocytes (Fig. 5A) demonstrated a diminished percentage of CD4+CD44hiCD62Llo memory T cells and an increased percentage of CD4+CD44loCD62Lhi naive T cells compared to Wt mice which resulted in an increased ratio of naive/memory CD4+ T cells in Tg mice compared to Wt controls (Fig. 5B). To assess lymphocytic demise, we evaluated apoptotic (annexin-V+7-ADD-) and necrotic (annexin-V+7-ADD+) lymphocytes among viable T cells (Thy-1+) and B cells (CD45R/B220+) from spleen cell isolates of early symptomatic (14 weeks old) B6SJL SOD1 Tg mice and Wt controls. Flow cytometric analysis revealed that Tg mice had a greater than 2-fold increase in the percentage of annexin-V+7-ADD+ necrotic splenic T cells and a 30% increase in the percentage of annexin-V+7-ADD- apoptotic T cells compared to Wt littermates (Fig. 5C). Similarly, percentages of necrotic (41%) and apoptotic (38%) B cells were increased in Tg mice compared to control mice.
###end p 62
###begin title 63
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Lymphocyte phenotype and function in G93A-SOD1 Tg mice.
###end title 63
###begin p 64
###xml 213 214 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 232 234 232 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 239 241 239 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 259 261 259 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 266 268 266 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 374 375 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 444 445 442 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 547 548 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 552 553 550 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 578 579 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 583 584 581 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 602 603 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 624 625 622 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 840 848 838 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 967 968 957 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 513 517 <span type="species:ncbi:10090">mice</span>
###xml 700 704 <span type="species:ncbi:10090">mice</span>
###xml 795 799 <span type="species:ncbi:10090">mice</span>
###xml 1100 1104 <span type="species:ncbi:10090">mice</span>
The phenotype and function of splenic lymphocytes from B6SJL SOD1 Tg and Wt littermates were assessed by flow cytometric analysis (FCM) and proliferation assays. (A) Representative dot plot for FCM analysis of CD4+ gated naive (CD44loCD62Lhi) and memory (CD44hiCD62Llo) T cells from Wt (left) and SOD1 Tg (right) mice at 14 weeks of age. (B) Mean percentages (+/-SEM) of CD4+ naive and memory T cells (left panel) and ratios of naive/memory CD4+ T cells (right panel) were determined for 5 Wt and 5 B6SJL SOD1 Tg mice. (C) Percentages of annexin-V+7ADD+ (necrotic) and annexin-V+7ADD- (apoptotic) Thy-1+ T cells or CD45RB220+ B cells amongst splenic lymphocytes were assessed in Wt and B6SJL SOD1 Tg mice at 14 weeks of age. (D) Lymphoproliferative responses of Wt littermates and B6SJL SOD1 Tg mice at 14 weeks of age were evaluated after in vitro stimulation for 3 days with anti-CD3 (1 microg/ml), anti-IgM (20 microg/ml), or media alone. Stimulation indices for [3H]-TdR uptake by splenocytes from each animal were determined from quadruplicate cultures and values represent the mean+/-SEM for 5 mice per group.
###end p 64
###begin p 65
###xml 373 380 373 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g005">Fig. 5D</xref>
###xml 467 474 467 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g001">Fig. 1F</xref>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 248 252 <span type="species:ncbi:10090">mice</span>
###xml 532 536 <span type="species:ncbi:10090">mice</span>
To assess lymphoid cell function of early symptomatic B6SJL SOD1 Tg mice at 14 weeks of age, we stimulated T cells with anti-CD3 and B cells with anti-IgM and evaluated their proliferative capacity of each lineage. T cell proliferation in B6SJL Tg mice was significantly diminished compared to Wt littermates; however no diminution of B cell function could be ascertained (Fig. 5D). The diminished T cell proliferative responses thus confirmed our previous findings (Fig. 1F). We also assessed whether lymphoid cells from Tg and Wt mice were differentially susceptible to activation-induced cell death at either 24 or 48 hrs post-activation, however no differences in induction of apoptotic or necrotic T or B cells at any time point after activation were observed (data not shown).
###end p 65
###begin title 66
###xml 23 27 <span type="species:ncbi:10090">Mice</span>
Survival of B6 SOD1 Tg Mice after Adoptive Transfer of Naive Lymphoid Cells, or Activated Treg or Teff Subsets
###end title 66
###begin p 67
###xml 425 426 425 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 553 572 553 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g006">Fig. 6A, p&#8202;=&#8202;0.2035</xref>
###xml 599 617 599 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g006">Fig. 6B, p&#8202;=&#8202;0.315</xref>
###xml 796 817 796 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g006">Fig. 6C, p&#8202;=&#8202;0.000001</xref>
###xml 952 971 952 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g006">Fig. 6D, p&#8202;=&#8202;0.0012</xref>
###xml 1036 1055 1036 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g006">Fig. 6E, p&#8202;=&#8202;0.0191</xref>
###xml 1220 1239 1220 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g006">Fig. 6F, p&#8202;=&#8202;0.2021</xref>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
###xml 643 647 <span type="species:ncbi:10090">mice</span>
###xml 757 761 <span type="species:ncbi:10090">mice</span>
###xml 893 897 <span type="species:ncbi:10090">mice</span>
###xml 1121 1125 <span type="species:ncbi:10090">mice</span>
###xml 1332 1336 <span type="species:ncbi:10090">mice</span>
Based on the above findings in SOD1 Tg mice demonstrating a lack of protective response by COP-1 immunization in male mice, diminished T cell functional capacity in early symptomatic and late stage mice, and end stage lymphopenia, we tested a strategy to rectify the lymphoid dysregulation and extend survival by adoptive transfer of B6 Wt naive lymphoid cells to recipient B6 SOD1 Tg mice. B6 SOD1 Tg mice treated with 50x106 naive spleen cells at 7, 13, and 19 weeks of age yielded no significant differences in the cumulative proportion of survival (Fig. 6A, p = 0.2035) or mean age of survival (Fig. 6B, p = 0.315) compared to PBS-treated mice. However, mean clinical scores analyzed by factorial ANOVA revealed significant improvement of reconstituted mice compared to PBS-treated controls (Fig. 6C, p = 0.000001). Additionally, Kaplan-Meier analysis showed immune reconstituted (RCS) Tg mice exhibited delayed symptom onset (clinical score = 3) (Fig. 6D, p = 0.0012) as well as delayed entry into late stage (clinical score = 1) (Fig. 6E, p = 0.0191). However, after onset of symptoms, survival of reconstituted Tg mice trended to be diminished compared to the PBS controls as determined by Kaplan-Meier analysis (Fig. 6F, p = 0.2021) and by mean latency after onset to death for PBS-treated (64.5+/-2.6) and RCS (52.0+/-4.3) mice (p = 0.0167) (data not shown).
###end p 67
###begin title 68
###xml 88 92 <span type="species:ncbi:10090">mice</span>
Effect of total lymphocyte reconstitution on survival and clinical scores in B6 SOD1 Tg mice.
###end title 68
###begin p 69
###xml 100 101 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 621 622 613 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 695 703 687 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 585 589 <span type="species:ncbi:10090">mice</span>
###xml 802 806 <span type="species:ncbi:10090">mice</span>
###xml 910 914 <span type="species:ncbi:10090">mice</span>
###xml 1106 1110 <span type="species:ncbi:10090">mice</span>
###xml 1204 1208 <span type="species:ncbi:10090">mice</span>
###xml 1328 1332 <span type="species:ncbi:10090">mice</span>
B6 SOD1 mice (20 mice/group) were treated with PBS (closed circles) or RCS (open circles) with 50x106 naive splenic lymphocytes. (A) Kaplan-Meier analysis of the proportion of surviving SOD1 Tg mice as a function of age. P = 0.2035 by Cox's F-test for comparison of PBS and RCS groups. (B) Mean age of survival+/-SEM for 20 mice/group treated with PBS (black bar, 149.3+/-7.5 days) or reconstituted with naive lymphocytes (RCS) (white bar, 151.5+/-7.5 days). Comparison of treatment groups indicated p = 0.315 by ANOVA. (C) Mean clinical scores (+/-SEM) of PBS- or RCS-treated SOD1 Tg mice as a function of age in weeks. *P<0.05 compared to PBS treated group by factorial ANOVA and Fisher's LSD post-hoc tests of treatment and age. (D) Kaplan-Meier analysis of age and cumulative proportion of SOD1 Tg mice reaching onset of disease (clinical score = 3). P = 0.0012 by Cox's F-test comparison of reconstituted mice to those treated with PBS. (E) Kaplan-Meier analysis of age and proportion of SOD1 Tg reaching late disease stage (clinical score = 1). P = 0.0191 by Cox's F-test comparison of reconstituted mice to those treated with PBS. (F) Kaplan-Meier analysis of the cumulative proportion of SOD1 Tg mice surviving after the time of disease onset (clinical score = 3). P = 0.2021 by Cox's F test comparison of RCS and those mice treated with PBS.
###end p 69
###begin p 70
###xml 134 142 134 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002740.s001">Fig. S1A</xref>
###xml 520 528 520 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002740.s001">Fig. S1B</xref>
###xml 661 669 661 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002740.s001">Fig. S1C</xref>
###xml 304 308 <span type="species:ncbi:10090">mice</span>
No significant differences in body weight were discerned between RCS- and PBS-treated groups as a function of age by factorial ANOVA (Fig. S1A, p = 0.5824). Additionally, no differences in PBS-treated or RCS groups were found in the cumulative proportion (p = 0.2744) and the mean age (p = 0.2921) of Tg mice that reach 10% loss of maximum body weight (data not shown). Although an early effect in hind grip strength was observed between 10-13 weeks of age as determined by PaGE, no effects were discernible thereafter (Fig. S1B). Factorial ANOVA indicated no differences in motor function as determined by ORP in PBS-treated or RCS groups over their lifetime (Fig. S1C, p = 0.8862).
###end p 70
###begin p 71
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Benner1">[23]</xref>
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Laurie1">[28]</xref>
###xml 146 150 146 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Reynolds1">[44]</xref>
###xml 274 275 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 318 319 318 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 323 324 323 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 338 339 338 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 343 344 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 477 484 477 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g007">Fig. 7A</xref>
###xml 512 519 512 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g008">Fig. 8A</xref>
###xml 753 773 753 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g007">Fig. 7B, p&#8202;=&#8202;0.00004</xref>
###xml 925 932 925 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g007">Fig. 7C</xref>
###xml 973 980 973 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g008">Fig. 8B</xref>
###xml 1182 1200 1182 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g007">Fig. 7D, p&#8202;=&#8202;0.002</xref>
###xml 1233 1250 1233 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g008">Fig. 8C, p&lt;0.0003</xref>
###xml 1477 1496 1477 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g007">Fig. 7E, p&#8202;=&#8202;0.0098</xref>
###xml 1643 1651 1643 1651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002740.s002">Fig. S2A</xref>
###xml 1858 1876 1856 1874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g007">Fig. 7F, p&#8202;=&#8202;0.003</xref>
###xml 1892 1899 1890 1897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g008">Fig. 8D</xref>
###xml 99 104 <span type="species:ncbi:10090">mouse</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
###xml 1059 1063 <span type="species:ncbi:10090">mice</span>
###xml 1904 1908 <span type="species:ncbi:10090">mice</span>
Based on our previous results which demonstrated that regulatory T cells were neuroprotective in a mouse model of Parkinson's disease [23], [28], [44], we evaluated whether activated T cell subsets also provide analogous protection in SOD1 Tg mice. Adoptive transfer of 1x106 enriched polyclonal-activated Wt Treg (CD4+CD25+) or Teff (CD4+CD25-) to B6 SOD1 Tg mice at 7, 13, and 19 weeks of age led to significant increases in longevity as determined by Kaplan-Meier analysis (Fig. 7A) and mean age of survival (Fig. 8A) compared to PBS-treated controls. Factorial ANOVA of treatment and age showed that by 11-12 weeks of age, clinical scores were increased by reconstitution of B6 Tg recipients with activated Wt Treg or Teff compared to PBS controls (Fig. 7B, p = 0.00004). Moreover, entry into late stage disease (clinical score = 1) was delayed by reconstitution with Treg or Teff as determined by Kaplan-Meier analysis (Fig. 7C) and mean age of entry into late stage (Fig. 8B). Of interest, transfer of activated Wt Treg, but not Teff to B6 Tg recipient mice delayed disease onset as evaluated by clinical signs (clinical score = 3) and as determined by Kaplan-Meier analysis (Fig. 7D, p = 0.002) and mean age of disease onset (Fig. 8C, p<0.0003). On the other hand, transfer of activated Wt Teff, but not Treg to B6 Tg recipients, increased the latency from onset (clinical score = 3) to entry into late stage (clinical score = 1) as determined by Kaplan-Meier analysis (Fig. 7E, p = 0.0098). Adoptive transfer of Treg or Teff affected weight gain and loss as determined by factorial ANOVA for effects of treatment as a function of age (Fig. S2A, p = 0.0356). Transfer of activated Teff, but not Treg delayed the age at which recipients lost >/=10% of maximum body weight compared to PBS treatment as determined by Kaplan-Meier analysis of proportion (Fig. 7F, p = 0.003) and mean age (Fig. 8D) of mice reaching >/=10% weight loss.
###end p 71
###begin title 72
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Effect of Treg and Teff on survival, clinical scores and weight loss in B6 SOD1 Tg mice.
###end title 72
###begin p 73
###xml 81 82 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 119 120 119 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 561 569 561 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
###xml 881 885 <span type="species:ncbi:10090">mice</span>
###xml 1124 1128 <span type="species:ncbi:10090">mice</span>
###xml 1428 1432 <span type="species:ncbi:10090">mice</span>
B6 G93A-SOD1 mice (14-15 mice/group) were treated with PBS (closed circles), 1x106 activated Treg (open boxes), or 1x106 activated Teff (open triangles) at 7, 13, and 19 weeks of age. (A) Kaplan-Meier analysis of the proportion of surviving SOD1 Tg mice as a function of age. Cox's F-test comparison of groups treated with PBS vs Treg (p = 0.0054) or Teff (p = 0.0002), and Treg vs Teff (p = 0.2505). (B) Clinical scores of SOD1 Tg mice as a function of age in weeks. *P<0.05 compared to PBS treated group at each time point by factorial ANOVA and Fisher's LSD post-hoc tests. (C) Kaplan-Meier analysis for age and proportion of SOD1 Tg reaching late disease stage (clinical score = 1). Cox's F-test comparison of groups treated with PBS vs Treg (p = 0.006) or Teff (p = 0.0003), and Treg vs Teff (p = 0.1883). (D) Kaplan-Meier analysis of age and cumulative proportion of SOD1 Tg mice reaching onset of disease (clinical score = 3). Cox's F-test comparison of groups treated with PBS vs Treg (p = 0.002) or Teff (p = 0.4215), and Treg vs Teff (p = 0.0014). (E) Kaplan-Meier analysis of the cumulative proportion of SOD1 Tg mice and the time after disease onset (clinical score = 3) to reach late stage (clinical score = 1). Cox's F test comparison of groups treated with PBS vs Treg (p = 0.2716) or Teff (p = 0.0098), and Treg vs Teff (p = 0.0055). (F) Kaplan-Meier analysis of the age and the cumulative proportion of SOD1 Tg mice that exhibited a reduction of maximum body weight >/=10%. Cox's F-test comparison of groups treated with PBS vs Treg (p = 0.2131) or Teff (p = 0.003), and Treg vs Teff (p = 0.0807).
###end p 73
###begin title 74
###xml 100 104 <span type="species:ncbi:10090">mice</span>
Effect of Treg and Teff on mean age of survival, clinical scores and weight loss in B6 G93A-SOD1 Tg mice.
###end title 74
###begin p 75
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 95 96 95 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 306 307 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 367 375 359 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 558 559 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 620 628 604 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 805 806 781 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 871 879 847 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 1076 1077 1042 1043 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 1138 1146 1104 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 667 671 <span type="species:ncbi:10090">mice</span>
###xml 918 922 <span type="species:ncbi:10090">mice</span>
B6 G93A-SOD1 mice were treated with PBS (black bars), 1x106 activated Treg (gray bars), or 1x106 activated Teff (white bars) at 7, 13, and 19 weeks of age. (A) Mean age of survival+/-SEM for 14-15 SOD1 Tg mice/group treated with PBS (152.7+/-2.0 days), Treg (165.8+/-5.0 days), or Teff (170.1+/-3.4 days). aP<0.04 compared to PBS-treated mice by ANOVA and Bonferroni post-hoc tests. (B) Mean age+/-SEM for SOD1 Tg mice reaching late stage (clinical score = 1) after treatment with PBS (136.9+/-3.1 days), Treg (153.5+/-5.8 days), or Teff (160.1+/-4.3 days). aP<0.04 compared to PBS control group by ANOVA and Bonferroni post-hoc tests. (C) Mean age+/-SEM for SOD1 Tg mice at disease onset (clinical score = 3) after treatment with PBS (77.7+/-1.3 days), Treg (89.8+/-2.7 days), or Teff (75.7+/-1.9 days). aP = 0.0003 compared to PBS control group by ANOVA and Bonferroni post-hoc tests. (D) Mean age+/-SEM for SOD1 Tg mice that exhibit a reduction of maximum body weight >/=10% after treatment with PBS (147.2+/-2.5 days), Treg (152.8+/-3.7 days), or Teff (159.7+/-4.0 days). aP<0.04 compared to PBS control group by ANOVA and Bonferroni post-hoc tests.
###end p 75
###begin p 76
###xml 196 204 196 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002740.s002">Fig. S2B</xref>
###xml 216 218 216 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 230 238 230 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002740.s002">Fig. S2C</xref>
###xml 250 253 250 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;11</sup>
###xml 376 383 376 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g009">Fig. 9A</xref>
###xml 399 406 399 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g009">Fig. 9B</xref>
###xml 593 600 591 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g009">Fig. 9C</xref>
###xml 620 627 618 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g009">Fig. 9D</xref>
###xml 891 898 887 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g009">Fig. 9E</xref>
###xml 924 931 920 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g009">Fig. 9F</xref>
###xml 1184 1191 1178 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g009">Fig. 9G</xref>
###xml 1207 1214 1201 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g009">Fig. 9H</xref>
###xml 1558 1565 1550 1557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002740-g009">Fig. 9G</xref>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 632 636 <span type="species:ncbi:10090">mice</span>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
###xml 1043 1047 <span type="species:ncbi:10090">mice</span>
###xml 1219 1223 <span type="species:ncbi:10090">mice</span>
###xml 1418 1422 <span type="species:ncbi:10090">mice</span>
Adoptive transfer of either Treg or Teff to B6 SOD1 Tg mice also improved motor function compared to PBS treated controls as determined by factorial ANOVA for effect of treatment with age on ORP (Fig. S2B, p = 3.3x10-8) and PaGE (Fig. S2C, p = 6.7x10-11). Activated Wt Treg or Teff delayed loss of rotarod performance as determined by Kaplan-Meier analysis of the proportion (Fig. 9A) and mean age (Fig. 9B) of mice at which >/=75% of ORP was reduced. Also transfer of activated Treg or Teff delayed the initial loss of ORP compared to PBS controls as determined by the cumulative percentage (Fig. 9C) and the mean age (Fig. 9D) of mice that reach >/=25% loss of ORP. We also assessed hind limb strength by PaGE. Compared to PBS controls, adoptive transfer of activated Treg or Teff delayed the loss of hind limb strength as determined by Kaplan-Meier analysis of the cumulative percentage (Fig. 9E) and increased mean age (Fig. 9F) of SOD1 Tg mice exhibiting >/=75% reduction of PaGE. In addition, transfer of activated Wt Treg or Teff to Tg mice delayed early loss of hind limb grip strength compared to controls as determined by Kaplan-Meier analysis of the cumulative percentage (Fig. 9G) and mean age (Fig. 9H) of mice that exhibit >/=25% reduction of PaGE. Of interest, after one round of Treg and Teff adoptive transfer at 49 days of age, Teff appear less efficient than Treg to attenuate early grip loss in Tg mice, however after a second round (at 91 days of age), the capacities to attenuate loss of grip strength by Teff and Treg were comparable (Fig. 9G).
###end p 76
###begin title 77
###xml 61 65 <span type="species:ncbi:10090">mice</span>
Effect of Treg and Teff on motor function in B6 G93A-SOD1 Tg mice.
###end title 77
###begin p 78
###xml 126 127 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 704 705 692 693 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 765 773 753 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 1214 1215 1190 1191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 1277 1285 1253 1261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 1771 1772 1735 1736 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 1835 1843 1799 1807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 2321 2322 2275 2276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 2383 2391 2337 2345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 306 310 <span type="species:ncbi:10090">mice</span>
###xml 545 549 <span type="species:ncbi:10090">mice</span>
###xml 565 569 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
###xml 852 856 <span type="species:ncbi:10090">mice</span>
###xml 1057 1061 <span type="species:ncbi:10090">mice</span>
###xml 1077 1081 <span type="species:ncbi:10090">mice</span>
###xml 1248 1252 <span type="species:ncbi:10090">mice</span>
###xml 1353 1357 <span type="species:ncbi:10090">mice</span>
###xml 1621 1625 <span type="species:ncbi:10090">mice</span>
###xml 1918 1922 <span type="species:ncbi:10090">mice</span>
###xml 2169 2173 <span type="species:ncbi:10090">mice</span>
B6 G93A-SOD1 mice (14-15 mice/group) were treated at 7, 13, and 19 weeks of age with PBS (closed circles and black bars), 1x106 activated Treg (open boxes and gray bars), or 1x106 activated Teff (open triangles and white bars). (A) Kaplan-Meier analysis of the age and the cumulative proportion of SOD1 Tg mice that exhibited a >/=75% reduction of overall rotarod performance (ORP). Cox's F-test comparison of groups treated with PBS vs Treg (p = 0.0377) or Teff (p = 0.0084), and Tregs vs Teffs (p = 0.27). (B) Mean age+/-SEM for 14-15 SOD1 Tg mice/group at which mice exhibited a >/=75% reduction in ORP after treatment with PBS (142.1+/-2.8 days), Treg (154.0+/-5.6 days), or Teff (157.5+/-4.4 days). aP<0.05 compared to PBS treated mice by ANOVA and Bonferroni post-hoc tests. (C) Kaplan-Meier analysis of ages and cumulative proportion of SOD1 Tg mice that exhibited >/=25% reduction in ORP. Cox's F-test comparison of groups treated with PBS vs Treg (p = 0.0054) or Teff (p = 0.0020), and Treg vs Teff (p = 0.20). (D) Mean age+/-SEM for 14-15 SOD1 Tg mice/group at which mice exhibited >/=25% reduction in ORP after treatment with PBS (117.7+/-3.5 days), Treg (136.5+/-6.2 days), or Teff (143.7+/-6.1 days). aP<0.0025 compared to PBS treated mice by ANOVA and Bonferroni post-hoc tests. (E) Kaplan-Meier analysis for age and proportion of SOD1 Tg mice that exhibited >/=75% reduction of maximum Paw Grip Endurance (PaGE) after treatment with PBS, Treg, or Teff. Cox's F test comparison of groups treated with PBS vs Treg (p = 0.001) or Teff (p = 0.0003), and Treg vs Teff (p = 0.14). (F) Mean age+/-SEM for SOD1 Tg mice that exhibited >/=75% reduction of maximum PaGE after treatment with PBS (94.5+/-5.6 days), Treg (131.1+/-4.2 days), or Teff (137.2+/-4.5 days). aP<0.0001 compared to PBS control group by ANOVA and Bonferroni post-hoc tests. (G) Kaplan-Meier analysis for age (days) and proportion of SOD1 Tg mice that exhibited >/=25% reduction of maximum PaGE after treatment with PBS, Treg, or Teff. Cox's F test comparison of groups treated with PBS vs Treg (p<0.0001) or Teff (p = 0.0033), and Treg vs Teff (p = 0.42). (H) Mean age+/-SEM at which SOD1 Tg mice exhibited at least 25% reduction of maximum PaGE after treatment with PBS (68.5+/-3.6 days), Treg (119.1+/-7.2 days), or Teff (108.7+/-11.3 days). aP<0.002 compared to PBS control group by ANOVA and Dunnett's post-hoc tests.
###end p 78
###begin title 79
###xml 56 64 <span type="species:ncbi:9606">Patients</span>
Preliminary Studies of Altered Adaptive Immunity in ALS Patients
###end title 79
###begin p 80
###xml 406 407 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 437 438 433 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 694 695 686 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 710 711 702 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 848 849 840 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 852 853 844 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 918 919 910 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 922 923 914 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1040 1041 1032 1033 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1198 1199 1186 1187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1222 1223 1210 1211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1345 1346 1329 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1369 1370 1353 1354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 298 306 <span type="species:ncbi:9606">patients</span>
###xml 726 734 <span type="species:ncbi:9606">patients</span>
###xml 787 795 <span type="species:ncbi:9606">patients</span>
###xml 1057 1065 <span type="species:ncbi:9606">patients</span>
To assess immune alterations in ALS patients, we characterized peripheral blood mononuclear cells (PBMC) from 10 ALS patients and 10 age-matched caregivers. Peripheral blood counts indicated a small, though insignificant increase in the number of leukocytes in patients compared to caregivers. ALS patients exhibited an increase in the mean percentage of polymorphonuclear neutrophils (PMNs) (8.0+/-0.07x109/L compared with 6.6+/-0.06x109/L, p = 0.022), with slightly reduced levels of lymphocytes (20.7%+/-2.4% compared with 25.9%+/-1.8, p = 0.054), and no discernible differences in monocyte levels (p = 0.35). Flow cytometric analysis showed no differences in levels of peripheral blood CD19+ B cells or CD3+ T cells among patients and caregivers. However compared to caregivers, ALS patients exhibited an 11.8% decrease in the percentage of CD4+CD8- T cells (p = 0.032) and a 22.9% increase in the frequency of CD4-CD8+ T cells (p = 0.043) compared to age-matched controls. Additionally, the CD45RA/CD45R0 (naive/memory) ratio among CD4+ T cells of ALS patients (0.6+/-0.1) was diminished by 45% compared to caregivers (1.1+/-0.2, p = 0.028), which was due to the diminution in levels of CD45RA+ naive T cell among CD4+ cells (37.2%+/-2.5% compared with 47.6%+/-5.1% for caregivers, p = 0.0435) and a concomitant increase in levels of CD45R0+ memory cells among CD4+ T cells (62.1%+/-2.6% compared with 51.7%+/-5.2% for caregivers, p = 0.0465).
###end p 80
###begin title 81
Discussion
###end title 81
###begin p 82
###xml 183 186 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Hall1">[5]</xref>
###xml 188 191 188 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Beers1">[8]</xref>
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Wu1">[12]</xref>
###xml 198 202 198 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Alexianu1">[31]</xref>
###xml 327 330 327 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Hall1">[5]</xref>
###xml 332 335 332 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-McGeer1">[6]</xref>
###xml 337 341 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Elliott1">[46]</xref>
###xml 342 346 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Yoshihara1">[49]</xref>
###xml 708 709 708 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 717 718 717 718 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 792 795 792 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-McGeer1">[6]</xref>
###xml 797 801 797 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Alexianu1">[31]</xref>
###xml 803 807 803 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Graves1">[32]</xref>
###xml 809 813 809 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Henkel2">[34]</xref>
###xml 814 818 814 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Troost1">[36]</xref>
###xml 918 922 918 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Zhang1">[41]</xref>
###xml 924 928 924 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Zhang2">[42]</xref>
###xml 977 981 977 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Goldknopf1">[50]</xref>
###xml 1045 1049 1045 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Desport1">[51]</xref>
###xml 1051 1055 1051 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Shi1">[52]</xref>
###xml 1095 1096 1095 1096 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1104 1105 1104 1105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1114 1118 1114 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Provinciali1">[53]</xref>
###xml 1379 1383 1379 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Nguyen1">[54]</xref>
###xml 1385 1389 1385 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-WyssCoray1">[55]</xref>
###xml 1526 1530 1526 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Baron1">[56]</xref>
###xml 1531 1535 1531 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Rentzos1">[59]</xref>
###xml 1622 1626 1622 1626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Casal1">[15]</xref>
###xml 1627 1631 1627 1631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Shalit1">[17]</xref>
###xml 1639 1643 1639 1643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-BarOr1">[18]</xref>
###xml 1645 1649 1645 1649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Filion1">[19]</xref>
###xml 2394 2402 2394 2402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2441 2442 2441 2442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2643 2647 2643 2647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Kuzmenok1">[60]</xref>
###xml 3250 3254 3250 3254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Scott1">[61]</xref>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 322 326 <span type="species:ncbi:10090">mice</span>
###xml 855 863 <span type="species:ncbi:9606">patients</span>
###xml 1131 1136 <span type="species:ncbi:9606">human</span>
###xml 1137 1145 <span type="species:ncbi:9606">patients</span>
###xml 1300 1305 <span type="species:ncbi:9606">human</span>
###xml 1517 1525 <span type="species:ncbi:9606">patients</span>
###xml 2019 2023 <span type="species:ncbi:10090">mice</span>
###xml 2214 2218 <span type="species:ncbi:10090">mice</span>
###xml 2638 2642 <span type="species:ncbi:10090">mice</span>
###xml 3112 3117 <span type="species:ncbi:10090">mouse</span>
###xml 3236 3241 <span type="species:ncbi:9606">human</span>
Recent evidence in SOD1 Tg ALS mice suggest neuroimmune dysregulation of microglia that play a role as key contributors of disease progression and in orchestrating motor neuron death [5], [8]-[12], [31]. Activation of glia cells and inflammatory processes coincide with disease onset and progression of disease in SOD1 Tg mice [5], [6], [46]-[49]. Postmortem examinations of ALS neural tissues reveal associations between innate immune and immune effector changes and exhibit reactive microglia, astrocytes, blood-borne macrophages, mast cells, increased number of dendritic cells, elevated chemoattractant factors, major histocompatibility complex (MHC) class I and II molecules, as well as infiltrating CD4+ and CD8+ T lymphocytes surrounding degenerating neurons and areas affected in ALS [6], [31], [32], [34]-[36]. Systemic immune aberrations in ALS patients include alterations in macrophage activation profiles [41], [42], elevated levels of complement proteins in sera [50], increased IL-13 producing T cells and circulating neutrophils [51], [52], lymphopenia with reduced number of CD2+ and CD8+ T cells [53]. Studies of human patients with neurodegenerative disorders including ALS, indicate increased expression of molecules associated with adaptive immunity, such as MHC class I, II and human leukocyte antigens in brains, spinal cords, cerebrospinal fluid and sera [54], [55]. Increased levels of monocyte chemoattractant protein (MCP)-1 and RANTES are detected in cerebrospinal fluid and sera from ALS patients [56]-[59]. Several reports support that peripheral immune activation plays a crucial role in AD [15]-[17] and MS [18], [19]. Based on this evidence of concomitant induction of adaptive immune responses and innate immune activation, the possibility of common immune-activating pathways in ALS and other neurodegenerative disorders justified the hypothesis for adaptive immune dysfunction as a major mechanism in neuroimmune dysregulation in ALS. Indeed, we demonstrated that spleens of SOD1 Tg mice at end stage display significant reductions in size and weight and profound lymphopenia. Further, splenic architecture and expression of lymphocyte antigens were markedly altered in SOD1 Tg mice. Moreover, these immune aberrations were preceded by several weeks prior to early disease with significant T cell functional deficits, decreased lymphoproliferative responses in vitro, altered ratios of naive to memory CD4+ T cells, and increased percentage of necrotic and apoptotic T cells. Taken together, our data in conjunction with a solitary report showing lymphopenia in peripheral blood of end stage G93A-SOD1 mice [60] strongly indicates the critical involvement of adaptive immune deficits in mutant SOD1-associated pathology, while early presentation of immune dysfunction prior to clinical symptoms and subsequent demise, strongly argues for the possibility that immune dysfunction and loss of adaptive immune cells reflect mechanisms other than those associated with end stage disease. Moreover, these data suggest a plausible explanation for the results observed in the SOD1 Tg mouse in which several drugs previously shown to be efficacious in survival studies, have failed to demonstrate efficacy in human studies [61].
###end p 82
###begin p 83
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Arnon1">[62]</xref>
###xml 89 93 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Teitelbaum1">[64]</xref>
###xml 158 162 158 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Neuhaus1">[65]</xref>
###xml 204 208 204 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Benner1">[23]</xref>
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Laurie1">[28]</xref>
###xml 473 477 473 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Angelov1">[37]</xref>
###xml 478 482 478 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Haenggeli1">[39]</xref>
###xml 803 807 803 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Habisch1">[38]</xref>
###xml 1463 1467 1463 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Haenggeli1">[39]</xref>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
###xml 601 605 <span type="species:ncbi:10090">mice</span>
###xml 770 774 <span type="species:ncbi:10090">mice</span>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
###xml 1025 1029 <span type="species:ncbi:10090">mice</span>
###xml 1261 1265 <span type="species:ncbi:10090">mice</span>
###xml 1450 1455 <span type="species:ncbi:10090">mouse</span>
Induction of Treg that secrete anti-inflammatory cytokines and neurotrophic factors [62]-[64], shifts from proinflammatory Th1 to anti-inflammatory Th2 cells [65], and attenuation of microglial responses [23], [28] have been linked to the immunomodulatory action of COP-1. Neuroprotective immunization strategies using COP-1 and COP-1 derivatives administered with or without complete Freund's adjuvant in low or high copy G93A-SOD1 Tg mice have yielded disparate outcomes [37]-[39]. In the present study, COP-1 immunization elicited protection in terms of enhanced survival to female G93A-SOD1 B6 Tg mice. As induction of Th2 cells is one mechanism by which COP-1 mediates neuroprotection and benefits with this strategy have been shown to be limited to female SOD1 Tg mice as shown here and elsewhere [38], this restricted level of neuroprotection was most probably due, at least in part, to diminished T cell immune function in male SOD1 Tg mice as demonstrated by the loss of antigen-induced responses in COP-1 immunized mice and, more so by the global dysfunction of T cell immune responses to the polyclonal stimulators anti-CD3 and Con A in pre-symptomatic and symptomatic stages of the disease. The outcome of COP-1 immunization in male G93A-SOD1 B6 Tg mice in our present study echoes the failure of TV-5010, a COP-1 derivative to enhance survival conducted in three independent studies in G93A B6SJL SOD1, G93A B6 SOD1 and G37R SOD1 mutant mouse models [39].
###end p 83
###begin p 84
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 515 519 <span type="species:ncbi:10090">mice</span>
We initially attempted to correct lymphoid homeostasis and global T cell dysfunction by reconstituting the peripheral immune compartment. However reconstitution of B6 SOD1 Tg mice with Wt naive splenocytes at regular intervals only transiently delayed clinical onset and entry to late stage, and yielded no significant effect on survival. This indicated that repopulation of the immune compartment, though capable of transient delay of early and late stage disease, was not sufficient to extend survival in SOD1 Tg mice.
###end p 84
###begin p 85
###xml 180 184 180 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Avidan1">[21]</xref>
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Benner1">[23]</xref>
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Laurie1">[28]</xref>
###xml 198 202 198 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Angelov1">[37]</xref>
###xml 204 208 204 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Reynolds1">[44]</xref>
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Schwartz1">[66]</xref>
###xml 216 220 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Town1">[67]</xref>
###xml 1395 1398 1395 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Boillee1">[1]</xref>
###xml 1400 1403 1400 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Beers1">[8]</xref>
###xml 1405 1408 1405 1408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Boillee2">[9]</xref>
###xml 1410 1414 1410 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Boillee3">[68]</xref>
###xml 1416 1420 1416 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Harraz1">[69]</xref>
###xml 1484 1488 1484 1488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Avidan1">[21]</xref>
###xml 1490 1494 1490 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Reynolds1">[44]</xref>
###xml 1496 1500 1496 1500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Kipnis2">[70]</xref>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 453 457 <span type="species:ncbi:10090">mice</span>
###xml 1390 1394 <span type="species:ncbi:10090">mice</span>
###xml 1596 1600 <span type="species:ncbi:10090">mice</span>
As regulatory T cells are known to suppress immune activation, maintain immune homeostasis, attenuate microglia activation and provide beneficial compensation in neurodegeneration [21], [23], [28], [37], [44], [66], [67], we next employed a reconstitution strategy with polyclonal-activated Wt Treg or Teff beginning at the pre-symptomatic stage of SOD1 Tg mice to maintain immune homeostasis and neurological function, and enhance longevity in SOD1 Tg mice. Not only did activated Treg attenuate motor deficits and enhance survival in Tg animals, but activated Teff were equally as effective for these parameters. Interestingly, Treg delayed the onset of symptoms, while Teff cells increased the latency from symptom onset to entry into the terminal phase and also delayed weight loss. Thus, these differential pathways toward a shared protective outcome of disease progression suggest distinct underlying mechanisms conferred by Treg and Teff in neuroprotection with the effects of Treg acting primarily on the afferent response limb. This is congruent with reported activities of CD4+CD25+ Treg and Teff; i.e., Treg typically act on afferent or induction of immune responses, whereas Teff are efferent effectors. Thus neuroprotective Treg and Teff most probably act via several independent pathways. The implication of macrophages and microglia in disease progression in ALS and SOD1 Tg mice [1], [8], [9], [68], [69] and evidence of Treg-mediated regulation of microglia function [21], [44], [70], suggest that Treg affect the induction phase of those cells. Delayed disease onset in SOD1 Tg mice supports that suggestion. On the other hand, the delay of entry to late stage disease after onset by activated Teff cells, suggests that protective populations are acting to attenuate already activated myeloid populations. These results taken together suggest a possible role for polyclonal-activated regulatory T cells in ALS therapy.
###end p 85
###begin p 86
###xml 105 108 105 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-McGeer1">[6]</xref>
###xml 252 253 252 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 356 357 356 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 711 715 711 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Curti1">[71]</xref>
###xml 774 778 774 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Poulopoulou1">[72]</xref>
###xml 853 857 853 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Cereda1">[73]</xref>
###xml 859 863 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Cova1">[74]</xref>
###xml 912 916 912 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Buttarelli1">[75]</xref>
###xml 1011 1015 1011 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Zhang1">[41]</xref>
###xml 1041 1045 1041 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Shi1">[52]</xref>
###xml 1082 1086 1082 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Sengun1">[76]</xref>
###xml 1358 1359 1358 1359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1384 1388 1384 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Provinciali1">[53]</xref>
###xml 1408 1409 1408 1409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1477 1481 1477 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Sinha1">[77]</xref>
###xml 1483 1487 1483 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Verma1">[78]</xref>
###xml 1814 1818 1814 1818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Hoffman1">[79]</xref>
###xml 1819 1823 1819 1823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002740-Hoffman3">[81]</xref>
###xml 1983 1984 1983 1984 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2141 2142 2141 2142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
###xml 444 452 <span type="species:ncbi:9606">patients</span>
###xml 532 540 <span type="species:ncbi:9606">patients</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
###xml 1155 1162 <span type="species:ncbi:9606">patient</span>
###xml 1260 1268 <span type="species:ncbi:9606">patients</span>
###xml 1375 1383 <span type="species:ncbi:9606">patients</span>
###xml 1421 1424 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1434 1442 <span type="species:ncbi:9606">patients</span>
###xml 1526 1534 <span type="species:ncbi:9606">patients</span>
###xml 1913 1917 <span type="species:ncbi:10090">mice</span>
###xml 1955 1959 <span type="species:ncbi:10090">mice</span>
###xml 2044 2052 <span type="species:ncbi:9606">patients</span>
###xml 2191 2197 <span type="species:ncbi:9606">humans</span>
###xml 2202 2206 <span type="species:ncbi:10090">mice</span>
###xml 2304 2310 <span type="species:ncbi:10090">murine</span>
###xml 2346 2351 <span type="species:ncbi:9606">human</span>
###xml 2430 2436 <span type="species:ncbi:10090">murine</span>
###xml 2539 2543 <span type="species:ncbi:10090">mice</span>
###xml 2597 2605 <span type="species:ncbi:9606">patients</span>
###xml 2786 2794 <span type="species:ncbi:9606">patients</span>
###xml 2810 2814 <span type="species:ncbi:10090">mice</span>
Immune dysregulation affecting both adaptive and innate immune systems have a consistent hallmark in ALS [6]. We report for the first time that compared to caregivers, ALS patients exhibited diminished CD45RA/CD45R0 (naive/memory) ratios within the CD4+ T cell subset. Diminished levels of naive (CD45RA) T cells and increased levels of memory (CD45R0) CD4+ T cells were coincidently responsible for diminution of naive/memory ratios among ALS patients. Evidence of dysregulation within the peripheral adaptive immune system of ALS patients reveals many adaptive immune deficits. Peripheral blood lymphocytes from ALS patients have been reported to exhibit abnormalities in mitochondrial and calcium metabolism [71], reduced levels of metabotropic glutamate receptor 2 mRNA [72], altered expression of antioxidant proteins and responses to nitric oxide [73], [74], and reduced expression of dopamine transporter [75]. More recent evidence that includes increased levels of circulating monocytes and macrophages [41], IL-13 producing T cells [52], and serum anti-Fas antibody levels [76] suggests a more activated peripheral immune system. Although in our patient cohort acute lymphopenia was not evident, the level of lymphocyte frequency trended lower in ALS patients. Nevertheless, evidence linking immunodeficiency in ALS syndromes include the loss of CD8+ T cells in ALS patients [53] and the loss of CD4+ T cells in HIV-infected patients that displayed ALS-like syndromes [77], [78]. Moreover, disease onset in Guamanian patients exhibiting ALS-inclusive syndromes has been linked to immunodeficiency and loss of T cell-mediated immunity including lymphopenia, diminished frequency and total number of peripheral T cells, diminished responses to skin-test antigens, and decreased T cell responses to mitogens [79]-[81]. These findings are in agreement with loss of T cell function and lymphopenia in SOD1 Tg mice. In contrast to 14 weeks old SOD1 Tg mice, which showed among CD4+ T cells, increased naive and decreased memory T cells, ALS patients in this study, exhibited a significant loss of naive CD4+ T cells and gain of memory CD4+ T cells. The reason for the discrepancy between humans and mice is not clear at this point, however possible explanations include contrasting differences in the murine model of familial ALS and sporadic human ALS, differences in homeostatic mechanism of peripheral blood lymphocytes and murine splenic T cells, or more likely, represents differences in T cell replenishment in relatively younger mice with a functional thymus compared to relatively aged patients in which thymic function is diminished. Nevertheless, compared to normal age-matched controls, our findings emphasize the peripheral immune dysfunction in T cell phenotypes in ALS patients and in SOD1 Tg mice, both T cell phenotype and function.
###end p 86
###begin p 87
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
###xml 519 523 <span type="species:ncbi:10090">mice</span>
###xml 551 555 <span type="species:ncbi:10090">mice</span>
###xml 720 728 <span type="species:ncbi:9606">patients</span>
Here, we present compelling evidence for adaptive immune deficits in ALS. Vaccination with COP-1 to induce regulatory T cells in G93A-SOD1 ALS mice that are genetically encoded for immune deficits, most probably underlies the failure of immune strategies to induce T cells resulting in lack of neuroprotective immune responses in SOD1 Tg mice. Reconstituting a dysfunctional immune system with activated T cell subsets, but not naive lymphocytes afforded improved neurological function and extended survival in SOD1 Tg mice. Thus, evidence in SOD1 Tg mice of progressive immunological deficits warrants caution in the interpretation of studies utilizing immunopharmacologic interventions in the SOD1 Tg model and in ALS patients.
###end p 87
###begin title 88
Supporting Information
###end title 88
###begin p 89
###xml 93 97 <span type="species:ncbi:10090">mice</span>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
###xml 1014 1018 <span type="species:ncbi:10090">mice</span>
Adoptive transfer of Wt naive lymphoid cells on weight and motor function of B6 G93A-SOD1 Tg mice. B6 G93A-SOD1 Tg mice (14-15 mice/group) were treated with PBS (closed circles) or 50x10 6 Wt naive spleen cells (open circles), i.v. (A) Mean body weights of treated SOD1 Tg mice were normalized to percentage of maximum weight (+/-SEM) and analyzed as a function of age in weeks. Factorial ANOVA of percent maximum body weights did not discern an effect of treatment (p = 0.1424) or of combined treatment and age (p = 0.5824). (B) Mean percentage of maximum paw grip endurance (PaGE)+/-SEM of treated SOD1 Tg mice were analyzed as a function of age in weeks. Factorial ANOVA did not discern a significant overall effect of treatment (p = 0.5840), but indicated a combined effect of treatment and age between 10 and 13 weeks of age (p = 0.001). *P<0.05 compared to PBS-treated group at each time point by Fisher's LSD post-hoc tests. (C) Mean percentage of overall rotarod performance (ORP)+/-SEM of treated SOD1 Tg mice were analyzed as function of age in weeks. Factorial ANOVA did not discern an effect of treatment (p = 0.7551) or combined effect of treatment and age (p = 0.8662).
###end p 89
###begin p 90
(1.00 MB DOC)
###end p 90
###begin p 91
Click here for additional data file.
###end p 91
###begin p 92
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 339 343 <span type="species:ncbi:10090">mice</span>
###xml 742 746 <span type="species:ncbi:10090">mice</span>
###xml 1049 1053 <span type="species:ncbi:10090">mice</span>
Adoptive transfer of anti-CD3 activated Wt Treg and Teff on weight and motor function of B6 G93A-SOD1 Tg mice. B6 G93A-SOD1 Tg mice (14-15 mice/group) were treated at 7, 13, and 19 weeks of age with PBS (closed circles), 1x106 activated Treg (open boxes), or 1x106 activated Teff (open triangles). (A) Mean body weights of treated SOD1 Tg mice were normalized to percentage of maximum weight+/-SEM and analyzed as function of age in weeks. Factorial ANOVA of percent maximum body weights indicated a significant combined effect of treatment and age (p = 0.0356). *P<0.05 compared to PBS-treated group at each time point by Fisher's LSD post-hoc tests. (B) Mean percentage of maximum overall rotarod performance (ORP)+/-SEM of treated SOD1 Tg mice analyzed as function of age in weeks. Factorial ANOVA indicated a significant combined effect of treatment and age (p = 3.3x10-8). *P<0.05 compared to PBS-treated group at each time point by Fisher's LSD post-hoc tests. (C) Mean percentage of maximum paw grip endurance (PaGE)+/-SEM of treated SOD1 Tg mice were analyzed as function of age in weeks. Factorial ANOVA indicated a significant combined effect of treatment and age (p = 6.7x10-11). *P<0.05 compared to PBS-treated group at each time point by Fisher's LSD post-hoc tests.
###end p 92
###begin p 93
(0.30 MB TIF)
###end p 93
###begin p 94
Click here for additional data file.
###end p 94
###begin p 95
The authors thank Ms. Carolyn Doorish for coordination and arrangement of the clinical blood specimens, and Ms. Linda Wilkie and Ms. Victoria Smith for technical assistance with flow cytometry.
###end p 95
###begin title 96
References
###end title 96
###begin article-title 97
ALS: a disease of motor neurons and their nonneuronal neighbors.
###end article-title 97
###begin article-title 98
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease.
###end article-title 98
###begin article-title 99
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.
###end article-title 99
###begin article-title 100
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 49 54 <span type="species:ncbi:9606">human</span>
Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.
###end article-title 100
###begin article-title 101
Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS.
###end article-title 101
###begin article-title 102
Inflammatory processes in amyotrophic lateral sclerosis.
###end article-title 102
###begin article-title 103
Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study.
###end article-title 103
###begin article-title 104
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis.
###end article-title 104
###begin article-title 105
Onset and progression in inherited ALS determined by motor neurons and microglia.
###end article-title 105
###begin article-title 106
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice.
###end article-title 106
###begin article-title 107
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Redox modifier genes in amyotrophic lateral sclerosis in mice.
###end article-title 107
###begin article-title 108
###xml 107 111 <span type="species:ncbi:10090">mice</span>
The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice.
###end article-title 108
###begin article-title 109
Alterations of T-lymphocyte populations in Parkinson disease.
###end article-title 109
###begin article-title 110
###xml 53 56 <span type="species:ncbi:10116">rat</span>
Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism.
###end article-title 110
###begin article-title 111
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Serum markers of monocyte/macrophage activation in patients with Alzheimer's disease and other types of dementia.
###end article-title 111
###begin article-title 112
Neutrophils CD11b and fibroblasts PGE(2) are elevated in Alzheimer's disease.
###end article-title 112
###begin article-title 113
T lymphocyte subpopulations and activation markers correlate with severity of Alzheimer's disease.
###end article-title 113
###begin article-title 114
Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis.
###end article-title 114
###begin article-title 115
Monocyte-derived cytokines in multiple sclerosis.
###end article-title 115
###begin article-title 116
###xml 142 146 <span type="species:ncbi:10090">mice</span>
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice.
###end article-title 116
###begin article-title 117
Vaccination with autoantigen protects against aggregated beta-amyloid and glutamate toxicity by controlling microglia: effect of CD4+CD25+ T cells.
###end article-title 117
###begin article-title 118
###xml 79 82 <span type="species:ncbi:10116">rat</span>
T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure.
###end article-title 118
###begin article-title 119
###xml 60 65 <span type="species:ncbi:10090">mouse</span>
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease.
###end article-title 119
###begin article-title 120
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
###end article-title 120
###begin article-title 121
###xml 95 101 <span type="species:ncbi:10090">murine</span>
###xml 111 116 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis.
###end article-title 121
###begin article-title 122
###xml 73 79 <span type="species:ncbi:10090">murine</span>
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Modulation of innate immunity by copolymer-1 leads to neuroprotection in murine HIV-1 encephalitis.
###end article-title 122
###begin article-title 123
T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies.
###end article-title 123
###begin article-title 124
###xml 40 44 <span type="species:ncbi:10090">mice</span>
CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
###end article-title 124
###begin article-title 125
T cell independent mechanism for copolymer-1-induced neuroprotection.
###end article-title 125
###begin article-title 126
T-cell-based immunity counteracts the potential toxicity of glutamate in the central nervous system.
###end article-title 126
###begin article-title 127
###xml 23 28 <span type="species:ncbi:10090">mouse</span>
Immune reactivity in a mouse model of familial ALS correlates with disease progression.
###end article-title 127
###begin article-title 128
Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells.
###end article-title 128
###begin article-title 129
###xml 95 100 <span type="species:ncbi:10090">mouse</span>
The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS.
###end article-title 129
###begin article-title 130
Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue.
###end article-title 130
###begin article-title 131
Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue.
###end article-title 131
###begin article-title 132
Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis.
###end article-title 132
###begin article-title 133
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
###end article-title 133
###begin article-title 134
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
Limited effects of glatiramer acetate in the high-copy number hSOD1-G93A mouse model of ALS.
###end article-title 134
###begin article-title 135
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS.
###end article-title 135
###begin article-title 136
Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia.
###end article-title 136
###begin article-title 137
Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS).
###end article-title 137
###begin article-title 138
MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS).
###end article-title 138
###begin article-title 139
Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia.
###end article-title 139
###begin article-title 140
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease.
###end article-title 140
###begin article-title 141
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
Assessing disease onset and progression in the SOD1 mouse model of ALS.
###end article-title 141
###begin article-title 142
###xml 27 33 <span type="species:ncbi:10090">murine</span>
Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis.
###end article-title 142
###begin article-title 143
###xml 147 152 <span type="species:ncbi:10090">mouse</span>
Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis.
###end article-title 143
###begin article-title 144
###xml 43 48 <span type="species:ncbi:10090">mouse</span>
Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis.
###end article-title 144
###begin article-title 145
###xml 113 118 <span type="species:ncbi:10090">mouse</span>
Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis.
###end article-title 145
###begin article-title 146
Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease.
###end article-title 146
###begin article-title 147
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis.
###end article-title 147
###begin article-title 148
Increased IL-13-producing T cells in ALS: positive correlations with disease severity and progression rate.
###end article-title 148
###begin article-title 149
Immunity assessment in the early stages of amyotrophic lateral sclerosis: a study of virus antibodies and lymphocyte subsets.
###end article-title 149
###begin article-title 150
Innate immunity: the missing link in neuroprotection and neurodegeneration?
###end article-title 150
###begin article-title 151
Inflammation in neurodegenerative disease-a double-edged sword.
###end article-title 151
###begin article-title 152
Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis.
###end article-title 152
###begin article-title 153
Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration.
###end article-title 153
###begin article-title 154
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of ALS patients.
###end article-title 154
###begin article-title 155
###xml 63 71 <span type="species:ncbi:9606">patients</span>
RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis.
###end article-title 155
###begin article-title 156
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
Lymphopenia and spontaneous autorosette formation in SOD1 mouse model of ALS.
###end article-title 156
###begin article-title 157
###xml 61 67 <span type="species:ncbi:10090">murine</span>
Design, power, and interpretation of studies in the standard murine model of ALS.
###end article-title 157
###begin article-title 158
Immunomodulation by the copolymer glatiramer acetate.
###end article-title 158
###begin article-title 159
Randomized controlled phase II trial of glatiramer acetate in ALS.
###end article-title 159
###begin article-title 160
Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.
###end article-title 160
###begin article-title 161
Mechanisms of action of glatiramer acetate in multiple sclerosis.
###end article-title 161
###begin article-title 162
Protective autoimmunity against the enemy within: fighting glutamate toxicity.
###end article-title 162
###begin article-title 163
Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).
###end article-title 163
###begin article-title 164
Revisiting oxidative damage in ALS: microglia, Nox, and mutant SOD1.
###end article-title 164
###begin article-title 165
SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model.
###end article-title 165
###begin article-title 166
Dual effect of CD4+CD25+ regulatory T cells in neurodegeneration: a dialogue with microglia.
###end article-title 166
###begin article-title 167
Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes.
###end article-title 167
###begin article-title 168
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Reduced expression of metabotropic glutamate receptor 2mRNA in T cells of ALS patients.
###end article-title 168
###begin article-title 169
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Effect of nitric oxide on lymphocytes from sporadic amyotrophic lateral sclerosis patients: toxic or protective role?
###end article-title 169
###begin article-title 170
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Modified expression of Bcl-2 and SOD1 proteins in lymphocytes from sporadic ALS patients.
###end article-title 170
###begin article-title 171
Dopamine transporter immunoreactivity in peripheral blood mononuclear cells in amyotrophic lateral sclerosis.
###end article-title 171
###begin article-title 172
Serum anti-Fas antibody levels in amyotrophic lateral sclerosis.
###end article-title 172
###begin article-title 173
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 clade-C-associated "ALS"-like disorder: first report from India.
###end article-title 173
###begin article-title 174
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 30 35 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
ALS syndrome in patients with HIV-1 infection.
###end article-title 174
###begin article-title 175
Immune function among normal Guamanians of different age.
###end article-title 175
###begin article-title 176
Cellular immunity in Guamanians with amyotrophic lateral sclerosis and Parkinsonism-dementia.
###end article-title 176
###begin article-title 177
Humoral immunity in Guamanians with amyotrophic lateral sclerosis and parkinsonism-dementia.
###end article-title 177
###begin p 178
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 178
###begin p 179
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was funded by grants from the National Institute of Neurological Disorders and Stroke Grants (NS36136, NS43985, NS007488, NS42269, NS38370, NS11766 and NS049264); National Institute of Mental Health (MH64570); National Institute of Aging (AG021617); National Institute of Environmental Health Sciences (ES013177); U.S. Department of Defense Grant (17-03-1); the Parkinson's Disease Foundation (CU51523606) and the Michael J. Fox Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 179

